GlassScriptPhysician profile
Kayla Jones
NPI 1750853271
$7,510.31
in general payments reported to CMS, 2019-2025
32 companies · $1,097 in 2025
The $1,097 reported for 2025 was more than what 86% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,808 · 2022: $1,544 · 2023: $1,629 · 2024: $1,432 · 2025: $1,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,157.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,700.09 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $1,676.65 | 2021-2025 | |
| Janssen Biotech, INC. | $584.10 | 2021-2025 | Stelara, Tremfya, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $478.35 | 2021-2025 | Entyvio, Eohilia |
| Intercept Pharmaceuticals, INC. | $419.75 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $327.91 | 2021-2024 | Dificid, Zinplava |
| Ironwood Pharmaceuticals, INC | $283.08 | 2021-2024 | Linzess |
| Evoke Pharma, INC. | $215.10 | 2021-2025 | Gimoti |
| Nestle Healthcare Nutrition INC. | $157.34 | 2021-2023 | |
| Genzyme Corporation | $155.86 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $144.30 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $126.89 | 2022-2025 | Dupixent |
| Paratek Pharmaceuticals, INC. | $124.99 | 2025 | Nuzyra |
| Qol Medical, LLC | $112.38 | 2023-2024 | Sucraid, Sucraid |
| Celgene Corporation | $111.26 | 2022-2024 | Zeposia |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $101.12 | 2021-2025 | |
| Vivus LLC | $100.75 | 2021-2022 | |
| Gilead Sciences, INC. | $88.35 | 2021-2025 | |
| Madrigal Pharmaceuticals | $82.89 | 2025 | Rezdiffra |
| Daiichi Sankyo INC. | $75.88 | 2021-2025 | Injectafer |
| Braintree Laboratories, INC. | $73.20 | 2021-2024 | Suflave, Sutab |
| Ipsen Biopharmaceuticals, INC | $67.78 | 2024-2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $57.62 | 2024-2025 | Zenpep |
| Redhill Biopharma INC. | $46.41 | 2021 | |
| Ardelyx, INC. | $45.46 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $42.79 | 2024-2025 | Omvoh |
| Organon LLC | $34.81 | 2023-2024 | Renflexis, Hadlima |
| Endogastric Solutions, INC | $18.39 | 2021 | |
| Medline Industries LP | $15.98 | 2025 | |
| Mauna Kea Technologies, INC. | $14.02 | 2025 | |
| Ethicon US, LLC | $13.79 | 2022 | |
| Medtronic, INC. | $13.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.